Chemomab Therapeutics Ltd. Sponsored ADR

CMMB Healthcare Biotechnology

In the quarter to June 2026, EPS grew 25.0% and free cash flow grew 47.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.27 0.02 −1.55%
Market cap
$9.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

10.49 9.08 10.31 6.41
Net Debt/EBITDA
5.53 5.25 4.35 2.98
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 (1.75) 0.00 (0.47)
Book value per Share
0.45 1.93 1.34 1.09
Free Cash Flow
— (11.13) — (3.75)
Other line items

Show all line items

Columns are period end dates